Study of a new drug for newly diagnosed multiple myeloma patients
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have newly diagnosed multiple myeloma that needs treatment and shows signs of active disease in blood or urine tests.
- You must be able to walk and take care of yourself (ECOG score of 0 to 2).
- Your kidney function, blood counts, and liver enzymes must meet certain levels in lab tests.
- You must be eligible for high-dose chemotherapy and a stem cell transplant.
- You must agree to use effective birth control and avoid pregnancy or donating eggs/sperm during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.